Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Timothy Z. Lehmberg(Dana-Farber Cancer Institute), Caron A. Jacobson(Dana-Farber Cancer Institute), Kerry A. Rogers(The Ohio State University), Erin M. Parry(Broad Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Samantha Pazienza(Dana-Farber Cancer Institute), Sarah Renner(The University of Texas MD Anderson Cancer Center), Philip A. Thompson(The Royal Melbourne Hospital), Udochukwu Ihuoma(Dana-Farber Cancer Institute), Zixu Wang(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), David C. Fisher(Dana-Farber Cancer Institute), Josie Montegaard(Dana-Farber Cancer Institute)
Cited by 75
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Towards personalized, tumour-specific, therapeutic vaccines for cancer
|Nature reviews. Immunology|2017|1k